Atopic Dermatitis News

• AAD 2022 Dermatology Residency Focuses on Rural Placement of Graduates The structure of the residency, which involves 3-month–long rotations at rural clinics in Mississippi, is designed to address the shortage of rural-based dermatologists in the United States.
  Medscape Medical News, May 11, 2022
• Atopic Dermatitis Treatment Is Evolving Dupilumab, an anti-IL-4 and anti-IL-13 monoclonal antibody, is indicated in Europe for the treatment of moderate to severe atopic dermatitis that requires systemic treatment.
  Medscape Medical News, May 04, 2022
• Allergic Dermatitis: What's the Optimum Duration for ROAT? Nearly all positive results appear sooner than the time currently recommended.
  Medscape Medical News, May 03, 2022
• Alert Upadacitinib Earns FDA Approval for Ankylosing Spondylitis Janus kinase inhibitor offers oral option for patients who have failed treatment.
  FDA Approvals, May 02, 2022
• Hairdresser Eczema Risk Far Outweighs That of Consumers "Oh, my poor hairdresser patients. The ones with hand eczema are so uncomfortable," said one dermatologist.
  Medscape Medical News, April 28, 2022
• More Evidence Links Asthma Severity to Age of Onset A large, international database study provides further evidence that age of asthma onset influences exacerbations and comorbidities.
  Medscape Medical News, April 27, 2022
• Skincare Products With Goat Milk Linked to New-Onset Food Allergy A new case series from Australia links goat-milk allergy to previous use of skincare products containing goat milk.
  Reuters Health Information, April 21, 2022
• Probiotic LGG Doesn't Lessen Eczema, Asthma, or Rhinitis Risk The researchers said they cannot support its use in this population of children at high risk for allergic disease.
  Medscape Medical News, April 18, 2022
• SOCS 2022 Study Finds Biopsy Decisions, Diagnoses Differ by Skin Type The survey investigated the role of skin color in the assessment of neoplastic and inflammatory skin conditions and decisions to perform biopsy.
  Medscape Medical News, April 11, 2022
• AAD 2022 JAK Inhibitors Improve Vitiligo, Trials Show Separate clinical trials of ruxolitinib and ritlecitinib showed both therapies resulted in significant repigmentation in patients with vitiligo.
  Medscape Medical News, April 08, 2022
• Obesity May Hinder Response to Immunotherapy for Allergies, Asthma, Mouse Study Suggests Obesity altered the immune system response to immunotherapy for allergies and asthma in a mouse study.
  Reuters Health Information, April 06, 2022
• Occupational Disinfectant Use During Pregnancy Tied to Eczema, Asthma in Offspring Pregnant women with frequent occupational exposure to disinfectant are at significantly increased risk of having children with eczema and asthma, new findings from Japan show.
  Reuters Health Information, April 01, 2022
• AAD 2022 COVID-19 Outcomes in AD Patients: Registry Data Reported Dupilumab monotherapy was associated with lower odds of hospitalizations compared with other therapies.
  Medscape Medical News, March 30, 2022
• ACDS 2022 Aluminum Named Allergen of the Year Though not a dangerous allergen, aluminum is ubiquitous and can even be found in Finn Chambers for patch testing.
  Medscape Medical News, March 25, 2022
• Adverse Skin Effects of Cancer Immunotherapy Reviewed A European task force has issued recommendations for the management of adverse skin reactions in patients with cancer receiving immune checkpoint inhibitors.
  Medscape Medical News, March 18, 2022
• Childhood Cold Allergy Lingers and Raises Risk for Anaphylaxis Children with cold urticaria had an elevated risk for anaphylaxis, and resolution often took years, a study from Canada reports.
  Medscape Medical News, March 18, 2022
• AAAAI 2022 Managing Overuse of Food IgE Panels: Multiple Approaches Needed Inappropriate food IgE testing remains problematic but educating doctors and families and limiting food panel ordering can make a difference.
  Medscape Medical News, March 04, 2022
• AAAAI 2022 Dupilumab Shows Benefits in Larger EoE Cohort In a phase 3 trial of adults and adolescents with hard-to-treat eosinophilic esophagitis, 6 months of weekly dupilumab sent 59% of participants into disease remission.
  Medscape Medical News, March 03, 2022
• ODAC 2022 Treating a Child With Severe AD: From Topicals to Biologics "Many patients who have failed topical steroids have never had adequate treatment," according to A. Yasmine Kirkorian, MD.
  Medscape Medical News, March 03, 2022
• Study Links Air Pollution to Psoriasis Flares More studies are needed to determine if the results are applicable to other populations and how air pollution might affect psoriasis disease activity, the investigators write.
  Medscape Medical News, February 24, 2022